|Various types of cancer kill roughly 1,600 people every single day in the U.S., with these numbers increasing over time due to the aging baby boomer population. Current treatments for cancer, such as radiation, chemotherapy, and surgery, are expensive, with the cost of cancer care forecast to reach $150 billion in the U.S. by 2020. Furthermore, current cancer treatments are invasive and aggressive; toxicity levels are high, causing side effects that are lasting and often causes more harm than good. Thus, there is continuous research on developing new instrumentation and procedures that reduce cancer treatment toxicity and cost and are more mobile and accessible to cancer and tumor patients.
Researchers at Purdue University have developed a method of using a minimally invasive technique of exploring and treating cancerous cells, tissues, and tumors without affecting nearby healthy cells. Photoporation (PP), electroporation (EP), and cold atmospheric plasma (CAP) are three techniques that appear promising in this quest, but have not previously been optimized for use. Researchers have optimized the parameters for these techniques for use on various different cancer cell lines. The approach can easily be combined with nanomedicines for further effective cancer treatment. The developed technique also aims to explore the synergy of these three treatments, PP, CAP, and EP, for significantly improving the efficacy of cancer treatment while minimizing the side effects of chemical treatments. Key innovations include effective, field-portable, cost effective, easy-to-use, and prototype ready technique for various biomedical applications including cancer. Improved mechanism of introducing active species generated from cold atmospheric plasma into the cells, tissues, tumors, and wounds by using photoporation and/or electroporation has shown an improved killing of cancer cells by almost 70 to 90 percent of very aggressive cancer cell lines. Additional fields of use for this technology include wound healing and bacteria disinfection.
-Targets cancerous cells without affecting healthy cells
-Improved efficiency of cancer cell apoptosis
-Reduced toxicity to the patient
-Reduced side effects
-More mobile and accessible to patients
Jan 12, 2018
Jan 20, 2017
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486